MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games

Microvascular Dropout

Search medical newsFind research, conditions and clinical updates
  • Home
  • Microvascular Dropout
Microvascular Dropout and Parapapillary Atrophy Progression Predict Structural Optic Disc Damage in Glaucoma Suspects
Posted innews Ophthalmology

Microvascular Dropout and Parapapillary Atrophy Progression Predict Structural Optic Disc Damage in Glaucoma Suspects

Posted by By MedXY 03/30/2026
A 19-year retrospective study reveals that microvascular dropout and β-zone parapapillary atrophy progression are powerful independent predictors of structural optic disc damage in glaucoma suspects, even when visual fields remain stable.
Read More
Microvascular Dropout as a Potent Biomarker for Structural Progression in Glaucoma Suspects
Posted innews Ophthalmology

Microvascular Dropout as a Potent Biomarker for Structural Progression in Glaucoma Suspects

Posted by By MedXY 03/16/2026
A retrospective cohort study reveals that microvascular dropout (MvD) and β-zone parapapillary atrophy (PPA) progression are significant independent predictors of structural optic disc damage in glaucoma suspect eyes, identifying risk long before the onset of perimetric visual field loss.
Read More

Take a game break

Explore a few games from MedXY.

Explore all games
  • Navigating Parental Refusal of Optimal Pediatric Cancer Treatments: Ethical Nuances of Trust and Nudging in Clinical Care
  • Ultrasound-Detected Presynovitis Predicts Rheumatoid Arthritis Onset in ACPA-Positive Individuals
  • Operationalizing Cardiac Xenotransplantation: A Comprehensive Administrative Playbook for Clinical Implementation
  • Brepocitinib Shows Promising Efficacy and Safety in Cutaneous Sarcoidosis: Results from a Phase 2 Randomized Clinical Trial
  • Evaluating the Impact of Timing on Cleft Palate Closure Outcomes: Insights from a Randomized Trial
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top